TMCnet News

Cellular Senescence a Double-Edged Sword: New Study Holds Implications for Aging, Cancer and Evolution
[December 03, 2008]

Cellular Senescence a Double-Edged Sword: New Study Holds Implications for Aging, Cancer and Evolution


BERKELEY, Calif., Dec 03, 2008 (ASCRIBE NEWS via COMTEX) --
Scientists
have identified a molecular cause behind the ravages of old
age and in doing so have also shown how a natural process
for fighting cancer in younger persons can actually promote
cancer in older individuals. Cellular senescence, the
process by which biological cells stop dividing in response
to stress or damage to their DNA, was shown to trigger the
secretion of proteins that cause inflammation in neighboring
cells and tissue. Inflammation is linked to almost every
major disease associated with aging, including many cancers.
Judith Campisi, a cell biologist who holds a joint
appointment with the U.S. Department of Energy's Lawrence
Berkeley National Laboratory (Berkeley Lab) and the Buck
Institute for Age Research, led this research.
"In this study, we provide for the first time a broad
molecular description of how cellular senescence, which is
well known as a mechanism for cancer prevention, also drives
aging and age-related disease by changing the local tissue
environment," she said. "Our study also defines a new
paradigm for how oncogenes promote and tumor suppressor
genes slow down the development of cancer, and provides new
evidence to support an evolutionary theory about aging."
The results of this study were published on-line by the
Public Library of Science (PLoS) in a paper entitled:
"Senescence-Associated Secretory Phenotypes Reveal
Cell-Nonautonomous Functions of Oncogenic RAS and the p53
Tumor Suppressor."
Co-authoring the paper with Campisi were Jean-Philippe
Coppe and Christopher Patil, members of Campisi's research
group in Berkeley Lab's Life Sciences Division, Joshua
Goldstein, now with the Novartis Research Foundation;
Francis Rodier and Denise Mu-oz of the Buck Institute; and
Peter Nelson and Yu Sun from the Fred Hutchinson Cancer
Research Center in Seattle.
The Good and the Bad of Cell Senescence
There are many different forms of cancer but all arise
from cell division run amok. Nature has evolved two ways of
shutting down cell-division and reining in uncontrolled
growth: apoptosis, or cell suicide, and senescence, in which
cells remain metabolically active but are no longer capable
of dividing. Apoptosis as a tumor suppressor has been well
characterized through in vivo studies, but the details of
cellular senescence have not been so clearly defined. It was
not until some 40 years after the process was first reported
in cultures that an in vivo assay developed by Campisi and
an earlier team of collaborators confirmed that it even
occurs in living organisms.
Following her assay work, Campisi, a leading authority on
cell senescence and the effects of aging, embarked upon
studies in mice that led her to propose three years ago that
with age an organism acquires enough senescent cells to
create conditions in cells and tissue that are conducive to
transforming benign lesions into malignant tumors. This
hypothesis helped explain why tumor incidence increases
exponentially with age.
"The evidence is increasing that genetic mutations alone
are insufficient for cancer development," Campisi said when
she first announced this hypothesis. "Rather, malignant
tumors also require a permissive tissue environment in which
to develop and progress."
In this latest research, she and her co-authors modified
commercial antibody arrays to substantially improve their
range and sensitivity, then measured the proteins secreted
by senescent cells in culture, as well as from tissue
samples that were collected from prostate cancer patients
both before and after completing a DNA-damaging form of
chemotherapy.
"We found that different types of cells from different
tissue all secrete a remarkably similar set of proteins when
they senesce in response to DNA-damaging radiation or
chemotherapy," Campisi said.
She and her co-authors branded this set of proteins as a
senescence-associated secretory phenotype, or SASP, and
determined that it occurs not only in cultured cells, but
also /in vivo/ in response to DNA damage.
"We showed that SASP develops slowly over several days
and only after DNA damage of sufficient magnitude to induce
senescence," Campisi said. "All SASP features high levels
of secreted inflammatory cytokines, immune modulators, and
growth factors, which are associated with inflammation and
malignancy."
Oncogenes and Tumor Suppressors
While Campisi and her co-authors found that secretion of
SASP was common to all senescent cells, there were distinct
quantitative and qualitative differences among the different
cell strains and lines. This paved the way for additional
findings concerning genes that encode tumor promoting
proteins (oncogenes) and those that encode tumor-suppressing
proteins. For example, normal cells that acquired a highly
active version of the RAS oncogene became senescent and
secreted higher levels of SASP components. This very intense
SASP also happened when cells lost the functions of the p53
tumor suppressor gene.
"Our findings help explain why senescent cells promote
the growth and aggressiveness of nearby pre-cancerous or
cancer cells, and define a new mechanism by which
pre-cancerous or cancer cells that have lost the p53 tumor
suppressor gene, or gained an oncogene such as RAS, promote
cancer so efficiently," Campisi said.
These findings also raise a cautionary note with regards
to the use of DNA-damaging chemotherapy on patients under
the age of 50. Such treatments are aimed at cells that are
undergoing rapid division but impact neighboring normal
cells as well. As the findings of Campisi and her co-authors
show, sufficient DNA damage forces both cancerous and normal
cells into senescence, releasing SASP components. The
resulting inflammation of neighboring cells and tissue would
explain why so many patients receiving chemotherapy
experience flu-like symptoms during treatments. Such
inflammation can also promote the development of further
cancers later in life.
"Chemotherapy can cure cancer but our results suggest
that this cure comes with a high cost and poses a risk that
could come back to haunt the patient," Campisi said. "There
is a great need for new biological therapies that more
effectively exploit the specific differences between normal
and cancer cells. Meanwhile, prevention remains the best
treatment for cancer."
Evolutionary Implications
The findings by Campisi and her co-authors that cellular
senescence can be beneficial to the young and deleterious to
the old provide what may be the first molecular evidence in
support of a major evolutionary theory on aging called
"antagonistic pleiotropy." This theory holds that natural
selection can favor a trait that contributes to early life
fitness even if that trait is harmful in older individuals.
"The dynamic we have shown between the cancer prevention
and aging effects of cellular senescence is an example of
the trade-offs between early fitness and late life survival,
exactly what is predicted by antagonistic pleiotropy," said
Campisi. "The challenge now is to preserve the anti-cancer
activity of cellular senescence while dampening its
pro-aging effects. Although senescent cells exist for the
good purpose of preventing cancer, we don't want them to
hang around - we want the body to be able to get rid of
them."
To this end, Campisi and her colleagues are now
developing mouse models through which they can determine
whether there are molecular pathways by which senescent
cells can either be safely expelled, or selectively
destroyed.
"Senescent cells are extremely stable and do not die,
therefore they accumulate in the body over time in multiple
tissues," she said. "The true test as to whether cellular
senescence is driving the pathologies associated with aging
will come if we are able to get rid of senescent cells in
our mouse model."
This work was supported by grants from the National
Institutes of Health.
Berkeley Lab is a U.S. Department of Energy national
laboratory located in Berkeley, California. It conducts
unclassified scientific research and is managed by the
University of California. Visit our Web site at
http://www.lbl.gov/ .
- - - -
NOTE TO EDITORS: An HTML version of this press release with
a video, images and links to additional information can be
viewed at
http://newscenter.lbl.gov/press-releases/2008/12/02/cellular-senescence/
((AScribe - The Public Interest Newswire / http://www.ascribe.org))

[ Back To TMCnet.com's Homepage ]